Alnylam Pharmaceuticals | ALNY - Gross Profit On Sales


Alnylam Pharmaceuticals reported $992.69M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
Arrowhead Research USD 75.25M 1.52M Jun/2026
BioCryst Pharmaceuticals USD 214.41M 61.36M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Incyte USD 1.57B 400.89M Jun/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
Moderna USD -566M 792M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 10.07B 758M Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.11B 343M Mar/2026
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Takeda JPY 813.22B 124.39B Jun/2026
Tectonic Therapeutic USD 0 0 Mar/2025
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026
Xencor USD 51.22M 46.7M Jun/2026